CRISPR Therapeutics AG Overview
Pro stress-test →CRISPR Therapeutics is a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has achieved significant milestones with its first approved product gaining market traction.
Strategic Profile
Pro stress-test →The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR is well positioned, with CASGEVY gaining momentum, and multiple programs with encouraging data demonstrating the transformative potential of CTX310 for patients suffering from severe cardiovascular disease, as well as zugo-cel in oncology and autoimmune diseases.
Competitive Landscape
Pro stress-test →CRISPR Therapeutics has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. Primary competitors in the gene editing space include Editas Medicine, Intellia Therapeutics, and Beam Therapeutics, which are also developing CRISPR-based therapies. The competitive advantage centers on CRISPR's first FDA-approved product and diversified pipeline across multiple therapeutic areas.
Industry Context
CRISPR Therapeutics AG operates in Biopharmaceuticals / Gene Editing Therapeutics.
Key facts
Founded: 2013 · Headquarters: Zug, Switzerland · Revenue: $0.864B